Paget Disease Treatment Market Report 2026

Paget Disease Treatment Market Overview

• Paget Disease Treatment market size has reached to $2.19 billion in 2025 • Expected to grow to $2.61 billion in 2030 at a compound annual growth rate (CAGR) of 3.6% • Growth Driver: Rising Cases Of Arthritis And Bone Injuries Boost Treatment Demand Due To Increasing Physical Inactivity • Market Trend: Innovative Product Development In The Market Driven By Advancements In Calcium Regulators • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Paget Disease Treatment Market?

Paget's disease is a chronic bone disorder characterized by abnormal bone remodeling, leading to weakened and enlarged bones. Treatment typically involves medications to regulate bone metabolism and manage symptoms, along with pain relievers and in some cases, surgery for severe bone deformities. The main types of paget disease treatment are actonel, reclast, zoledronic acid, fosamax, miacalcin, aredia, calcitonin, zometa, and other treatments. Actonel is a brand name for the medication risedronate, used to treat and prevent osteoporosis by strengthening bones. These treatments used various routes of administration, such as oral, intravenous, and topical; also, they are distributed through different distribution channels like hospital pharmacies, retail pharmacies, online pharmacies, and drug stores. The key end users are hospitals, clinics, and other end users.

What Is The Paget Disease Treatment Market Growth Forecast?

The paget disease treatment market size is expected to see steady growth in the next few years. It will grow to $2.61 billion in 2030 at a compound annual growth rate (CAGR) of 3.6%. The growth in the forecast period can be attributed to emergence of novel paget disease therapies, increasing adoption of targeted drug formulations, growth in minimally invasive surgical procedures, rising telehealth adoption for chronic bone disorders, expansion of online and retail pharmacy distribution channels. Major trends in the forecast period include rising adoption of bisphosphonate therapies, integration of personalized medicine approaches, growth in minimally invasive surgical interventions, increasing use of telemedicine for bone disorder management, expansion of online pharmacies for treatment access.

Global Paget Disease Treatment Market Segmentation

1) By Treatment Type: Actonel, Reclast, Zoledronic Acid, Fosamax, Miacalcin, Aredia, Calcitonin, Zometa, Other Treatments 2) By Route Of Administration: Oral, Intravenous, Topical 3) By Distribution Channels: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug stores 4) By End User: Hospitals, Clinics, Other End-Users Subsegments: 1) By Actonel: Risedronate Sodium Tablets, Delayed-Release Risedronate 2) By Reclast: Intravenous Reclast, Annual Reclast Infusion 3) By Zoledronic Acid: Zoledronic Acid 5 mg Injection, Zoledronic Acid 4 mg Injection 4) By Fosamax: Alendronate Sodium Tablets, Alendronate Oral Solution 5) By Miacalcin: Miacalcin Nasal Spray, Miacalcin Injection 6) By Aredia: Pamidronate Disodium 30 mg Injection, Pamidronate Disodium 90 mg Injection 7) By Calcitonin: Synthetic Salmon Calcitonin, Human Calcitonin 8) By Zometa: Zometa 4 mg/5 mL Concentrate, Zometa 4 mg Infusion 9) By Other Treatments: Pain Management Medications, Physical Therapy, Surgical Interventions

What Is The Driver Of The Paget Disease Treatment Market?

The rise in the number of cases related to arthritis and bone injuries is expected to propel the growth of the paget disease treatment market going forward. Arthritis is a condition that causes joint inflammation, whereas bone injuries can contribute to its development. The rise in arthritis and bone injuries can be attributed to a lack of physical activity, which weakens muscles and joints, reducing their ability to support movement and absorb impact. This increases the risk of joint degeneration, stiffness, and fractures over time. Paget disease treatment helps manage arthritis and bone injuries by reducing bone pain, improving joint function, and preventing complications such as fractures and deformities caused by abnormal bone remodeling. For instance, in February 2024, according to Arthritis Australia, an Australia-based not-for-profit organization focused on arthritis awareness, advocacy, and support, approximately 15% of Australians across all age groups are living with arthritis, making it one of the nation’s most prevalent chronic health conditions. Projections indicate that the arthritis patient population is expected to rise to 5.39 million by 2040, reflecting 31% growth and representing an additional 1.28 million affected individuals. By 2040, the number of people living with rheumatoid arthritis is projected to reach 280,040 males and 479,828 females. Therefore, the rise in the number of cases related to arthritis and bone injuries is driving growth in the paget disease treatment industry.

Key Players In The Global Paget Disease Treatment Market

Major companies operating in the paget disease treatment market are Pfizer Inc., Merck & Co. Inc., Novartis AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Limited, Apotex Inc., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Cipla Limited, Zakłady Farmaceutyczne Polpharma S.A., Amgen Inc., Sanofi S.A., GlaxoSmithKline plc, Johnson & Johnson, Roche Holding AG, AstraZeneca, Mallinckrodt Pharmaceuticals, Neopharma Inc., Kyowa Kirin Co. Ltd., Radius Health Inc., Accord Healthcare Ltd., Leucadia Pharmaceuticals Inc., Biocon Ltd., Omeros Corp., Angitia Biopharmaceuticals, CSPC Pharmaceutical Group Ltd., Luye Pharma Group Ltd.

Global Paget Disease Treatment Market Trends and Insights

Major companies operating in the paget disease treatment market are focusing on innovative product development, such as calcium regulators, to enhance treatment efficacy, improve patient outcomes, and expand their market presence. A calcium regulator is a substance or medication that helps control the levels of calcium in the blood and bones, maintaining balance to support various physiological functions. For instance, in February 2025, Fresenius Kabi AG, a Germany-based healthcare company, launched Calcitonin Salmon Injection, USP Synthetic, a calcium regulator designed to treat symptomatic Paget’s disease of the bone, hypercalcemia, and postmenopausal osteoporosis. This launch is aimed at offering a more cost-effective treatment option, strengthening their supply chain, and expanding their portfolio of generic injectables. Fresenius Kabi has made substantial investments in its facilities to guarantee a steady supply of essential medicines, with the objective of enhancing patient care and establishing itself as a leading healthcare provider.

What Are Latest Mergers And Acquisitions In The Paget Disease Treatment Market?

In June 2024, Sun Pharmaceutical Industries Limited, an India-based pharmaceutical company, acquired Taro Pharmaceutical for approximately $347.73 million. The aim of this acquisition is to gain full control of Taro Pharmaceutical Industries Ltd., enhancing Sun Pharma's dermatology and specialty generics portfolio while streamlining operations and maximizing synergies. Taro Pharmaceutical Industries Ltd. is an Israel-based pharmaceutical company specializing in generic and specialty medicines, including treatments for Paget’s disease.

Regional Outlook

North America was the largest region in the paget disease treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Paget Disease Treatment Market?

The paget disease treatment market consists of revenues earned by entities by providing services such as diagnosis services, orthopedic services, genetic counseling services, and follow-up and monitoring services. The market value includes the value of related goods sold by the service provider or included within the service offering. The paget disease treatment market also includes sales of pain management medications, calcium and vitamin D supplements, bone density monitoring devices, and assistive devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Paget Disease Treatment Market Report 2026?

The paget disease treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the paget disease treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.